Companies Dominating the Oncology Adjuvants Landscape
- Sanofi S.A
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Amgen Inc.
- Bristol Myers Squibb
- Eli Lilly and Company
- Biogen AstraZeneca plc
- Pfizer Inc.
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- SL Pharmaceutical
- Sanjiu Medical
- Hisun Pharmaceuticals USA Inc.
Browse Key Market Insights with Data Illustration:
In the News
- The benefit and feasibility of a novel approach to surgical treatment in NSCLC was demonstrated by the AEGEAN trial in June 2021. In patients with non-small cell lung cancer, combining neoadjuvant durvalumab with platinum-based chemotherapy, taken after by curative-intent surgery and adjuvant durvalumab progressed antitumor action and diminished repeat chance. In addition, perioperative durvalumab increased the rate of pathologic complete response by 12.9% when compared to placebo.
- Merck known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as a single agent, for adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB, II, or IIIA non-small cell lung cancer.
